The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function
Open accessAbstract
Aptamers are powerful candidates for molecular imaging applications due to a number of attractive features, including rapid blood clearance and tumor penetration. We carried out structure-activity relationship (SAR) studies with the Tenascin-C binding aptamer TTA1, which is a promising candidate for application in tumor imaging with radioisotopes. The aim was to improve its in vivo stability and target binding. We investigated the effect of thermal stabilization of the presumed non-binding double-stranded stem region on binding affinity and resistance against nucleolytic degradation. To achieve maximal thermal stem stabilization melting experiments with model hexanucleotide duplexes consisting of unmodified RNA, 2'-O-methyl RNA (2'-OMe), 2'-Fluoro RNA (2'-F) or Locked Nucleic Acids (LNAs) were initially carried out. Extremely high melting temperatures have been found for an LNA/LNA duplex. TTA1 derivatives with LNA and 2'-OMe modifications within the non-binding stem have subsequently been synthesized. Especially, the LNA-modified TTA1 derivative exhibited significant stem stabilization and markedly improved plasma stability while maintaining its binding affinity to the target. In addition, higher tumor uptake and longer blood retention was found in tumor-bearing nude mice. Thus, our strategy to introduce LNA modifications after the selection procedure is likely to be generally applicable to improve the in vivo stability of aptamers without compromising their binding properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Mathews, D. H., Sabina, J., Zuker, M., & Turner, D. H. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2700 · Cited by 3,795
Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics
Jayasena, S. D. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.9.1628 · Cited by 2,144
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
LNA: a versatile tool for therapeutics and genomics
Petersen, M., & Wengel, J. (2003) · Trends in Biotechnology · doi:10.1016/s0167-7799(02)00038-0 · Cited by 613
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA
Braasch, D. A., & Corey, D. R. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00058-2 · Cited by 605
Tenascin: An Extracellular Matrix Protein Prominent in Specialized Embryonic Tissues and Tumors
Erickson, H. P., & Bourdon, M. A. (1989) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.05.110189.000443 · Cited by 605
Design of antisense oligonucleotides stabilized by locked nucleic acids
Kurreck, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.1911 · Cited by 577
Daniels, D. A., Chen, H., Hicke, B. J., Swiderek, K. M., & Gold, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2136683100 · Cited by 567
Cited by
SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands
Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.06.001 · Cited by 1,430
Development of DNA aptamers using Cell-SELEX
Sefah, K., Shangguan, D., Xiong, X., O'Donoghue, M. B., & Tan, W. (2010) · Nature Protocols · doi:10.1038/nprot.2010.66 · Cited by 918
Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy
Famulok, M., Hartig, J. S., & Mayer, G. (2007) · Chemical Reviews · doi:10.1021/cr0306743 · Cited by 887
Current approaches in SELEX: An update to aptamer selection technology
Darmostuk, M., Rimpelova, S., Gbelcova, H., & Ruml, T. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.02.008 · Cited by 702
Aptamers from Cell-Based Selection for Bioanalytical Applications
Tan, W., Donovan, M. J., & Jiang, J. (2013) · Chemical Reviews · doi:10.1021/cr300468w · Cited by 649
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 589
Replacing antibodies with aptamers in lateral flow immunoassay
Chen, A., & Yang, S. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.04.041 · Cited by 551
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
Sun, H., Zhu, X., Lu, P. Y., Rosato, R. R., Tan, W., & Zu, Y. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.32 · Cited by 541
Rohloff, J. C., Gelinas, A. D., Jarvis, T. C., Ochsner, U. A., Schneider, D. J., Gold, L., & Janjic, N. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.49 · Cited by 533
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
Odeh, F., Nsairat, H., Alshaer, W., Ismail, M. A., Esawi, E., Qaqish, B., Bawab, A. A., & Ismail, S. I. (2019) · Molecules · doi:10.3390/molecules25010003 · Cited by 415
Röthlisberger, P., & Hollenstein, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.007 · Cited by 413
Lee, J. F., Stovall, G. M., & Ellington, A. D. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.03.015 · Cited by 398
Tenascin-C induced signaling in cancer
Orend, G., & Chiquet-Ehrismann, R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.02.017 · Cited by 384
Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Ni, X., Castanares, M., Mukherjee, A., & Lupold, S. E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797189600 · Cited by 349
Shi, H., He, X., Wang, K., Wu, X., Ye, X., Guo, Q., Tan, W., Qing, Z., Yang, X., & Zhou, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016197108 · Cited by 301
Komiyama, M., Yoshimoto, K., Sisido, M., & Ariga, K. (2017) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20170156 · Cited by 296
Recent advances in mycotoxins detection
Chauhan, R., Singh, J., Sachdev, T., Basu, T., & Malhotra, B. D. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.03.004 · Cited by 292
Perspectives on Chemistry and Therapeutic Applications of Locked Nucleic Acid (LNA)
Kaur, H., Babu, B. R., & Maiti, S. (2007) · Chemical Reviews · doi:10.1021/cr050266u · Cited by 285
Campbell, M. A., & Wengel, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15048k · Cited by 279
Investigations on the interface of nucleic acid aptamers and binding targets
Cai, S., Yan, J., Xiong, H., Liu, Y., Peng, D., & Liu, Z. (2018) · The Analyst · doi:10.1039/c8an01467a · Cited by 278
Aptamers and the next generation of diagnostic reagents
Thiviyanathan, V., & Gorenstein, D. G. (2012) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201200042 · Cited by 275
Therapeutic RNA aptamers in clinical trials
Sundaram, P., Kurniawan, H., Byrne, M. E., & Wower, J. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.10.014 · Cited by 259
Nanoparticle–aptamer bioconjugates for cancer targeting
Farokhzad, O. C., Karp, J. M., & Langer, R. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.3.311 · Cited by 256
Augmentation of DNA exonuclease TREX1 in macrophages as a therapy for cardiac ischemic injury
Ibrahim, A. G.-E., Ciullo, A., Komuro, H., Miyamoto, K., Jones, X. M., Yamaguchi, S., Tsi, K., Anderson, J., Godoy Coto, J., Kitka, D., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adp1338 · Cited by 12
Metadata
- Authors
- Schmidt, K. S.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-10-28
- Volume
- 32
- Issue
- 19
- Pages
- 5757-5765
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2075458316
- Cited by
- 287
- References
- 41
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.